A propensity analysis of AURA-LV plus AURORA 1 vs ALMS to compare a voclosporin-based, triple immunotherapy regimen to high-dose glucocorticoid-based immunosuppressive therapy (NKF-SCM 2024) - Mar 23, 2024 - Abstract #383; "In ALMS, MMF (3 g/day) or IV cyclophosphamide (IVC; 0.5 to 1.0 g/m2/month x 6) was added to oral GCs initiated at a maximum dose of 60 mg/day, tapered every 2 weeks to 10 mg/day. Treatment with the VCS-based triple immunosuppressive regimen resulted in an overall lower incidence of AEs and improved efficacy. These data further support the use of VCS-based triple therapy as initial treatment in patients with active LN and the need to re-evaluate the conventional high-dose 'dual' therapies."
Cardiovascular • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Kenneth Kalunian; Anca Askanase; Maria Dall'Era; Neil Solomons; Matt Truman; Lucy S Hodge; Ernie Yap
|